Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab.
Ogata
Atsushi
A
Morishima
Atsuyoshi
A
Hirano
Toru
T
Hishitani
Yoshihiro
Y
Hagihara
Keisuke
K
Shima
Yoshihito
Y
Narazaki
Masashi
M
Tanaka
Toshio
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D019947:Receptors, Interleukin-6 / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D006442:Glycated Hemoglobin; D019947:Receptors, Interleukin-6; C517652:hemoglobin A1c protein, human; C502936:tocilizumab